NCT04752735

Brief Summary

This is a retrospective real world registry study, aiming to explore the effectiveness and safety of endovascular treatment of acute ischemic stroke in a Chinese population.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 10, 2021

Completed
2 days until next milestone

First Posted

Study publicly available on registry

February 12, 2021

Completed
1 month until next milestone

Study Start

First participant enrolled

March 22, 2021

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 8, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 8, 2023

Completed
Last Updated

February 10, 2023

Status Verified

February 1, 2023

Enrollment Period

1.9 years

First QC Date

February 10, 2021

Last Update Submit

February 8, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Proportion of patients with modified Rankin Score (mRS) 0 to 2

    the minimum and maximum values of mRS are 0 and 6, respectively; higher mRS mean a worse outcome

    Day 90

Secondary Outcomes (7)

  • Changes in National Institute of Health stroke scale (NIHSS)

    Day 2, 7, 14

  • Proportion of patients with modified Rankin Score 0 to 2

    Day180, 360

  • Distribution of modified Rankin Score

    Day 90, 180, 360

  • Proportion of symptomatic intracranial hemorrhage (sICH)

    48 hours

  • Proportion of intraparenchymal hemorrhage (PH1 and PH2)

    48 hours

  • +2 more secondary outcomes

Interventions

all enrolled patients must receive endovascular treatment.

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

all patients must receive endovascular treatment regardless of the time from onset to treatment.

You may qualify if:

  • Age: ≥ 18;
  • Ischemic stroke confirmed by head CT or MRI;
  • Patients receiving endovascular treatment;
  • First ever stroke or mRS≤2 after previous disease;
  • Complete and clear pre- and post-operative DSA images are available

You may not qualify if:

  • Imaging data not qualified for evaluation;
  • Absence of important clinical data;
  • The first 50 patients receiving endovascular treatment in a single centerr.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Neurology, General Hospital of Northern Theater Command

Shenyang, 110016, China

Location

Related Publications (1)

  • Xing GP, Li W, Cui C, Zhao ZA, Nguyen TN, Chen HS. Thrombolysis to Recanalization Time Affects the Benefit of Bridging Thrombolysis in Large Vessel Occlusion Patients With Successful Recanalization. CNS Neurosci Ther. 2025 Sep;31(9):e70579. doi: 10.1111/cns.70579.

MeSH Terms

Conditions

Stroke

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of Neurology

Study Record Dates

First Submitted

February 10, 2021

First Posted

February 12, 2021

Study Start

March 22, 2021

Primary Completion

February 8, 2023

Study Completion

February 8, 2023

Last Updated

February 10, 2023

Record last verified: 2023-02

Locations